Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.

Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 Jul 03;: Authors: Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ Abstract The treatment of adult acute lymphoblastic leukemia (ALL) has largely followed the successful pediatric model that uses multi-agent chemotherapy regimens. Although cytotoxic chemotherapy can induce complete remissions, elderly patients are frequently unable to tolerate its intensity owing to toxicities and comorbidities. Elderly patients particularly often relapse, leading to a 5-year overall survival (OS) of only 20%. In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; chimeric antigen receptor T-cell therapies; and BH3 mimetics. Here, we discuss advancements in the treatment of ALL and their places in the armamentarium for adult patients. PMID: 31307896 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research

Related Links:

The study focused on the survival rate in patients with acute lymphoblastic leukemia (ALL). A total of 8305 ALL patients undergoing chemotherapy from the SEER database. Included patients were divided into thede novo ALL group (n=7454) and sALL group (n=851). Results showed the decreased survival rate of ALL with aging. sALL patients (18-75 years) had poorer prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 5 April 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Josep-Maria Ribera, Olga García, Eduardo Cerello Chapchap, Cristina Gil, José González-Campos, Pere Barba, María-Luz Amigo, María-José Moreno, Esperanza Lavilla, Natalia Alonso, Juan-Miguel Bergua, Mar Tormo, Jordi Ribera, Magdalena Sierra, Daniel Martínez-Carballeira, Santiago Mercadal, Jesús-María Hernández-Rivas, Ferran Vall-llovera, Eulàlia Genescà, Antònia Cladera
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In a series of 72 older and elderly frail patients (Charlson Comorbidity Index ≥4) with Philadelphia chromosome-negative ALL prospectively treated with very attenuated chemotherapy regimen (vincristine, dexamethasone, methotrexate and mercaptopurine) the rate of complete remission was 54%, with overall survival probability of 7.6 months. Patients with ECOG score
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: April 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 4Author(s): Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J. Short, Caitlin R. Rausch, Jonathan M. Savoy, Prithviraj Bose, Musa Yilmaz, Nitin Jain, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Michael Rytting, Partow Kebriaei, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The treatment and outcome in acute lymphoblastic leukemia (ALL) is dependent on risk stratification, based on certain prognostic factors including the leukemia subtype, severity of disease in terms of leukocyte count, age at diagnosis&presence of favourable/ unfavourable cytogenetic alterations, including recurrent translocations. In addition, cellular response to the initial treatment also plays guiding role in continuation or intensification of the chemotherapy. The discovery of genetic alterations like BCR-ABL1 and subsequent development of risk stratification strategies and targeted therapy has played a major role ...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 30 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J. Short, Caitlin R. Rausch, Jonathan M. Savoy, Prithviraj Bose, Musa Yilmaz, Nitin Jain, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Michael Rytting, Partow Kebriaei, Marina Konopleva, Hagop Kantarjian, Farhad RavandiAbstractBackgroundPatients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) have dismal outcomes. Preclinical studies suggest that T-ALL cells are sensitive to BCL2 inhibition. Clinical activity of venetocla...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Combination therapies that included venetoclax were administered to 13 patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma at our institution. Bone marrow responses were achieved in  60% of the evaluable patients, and 2 patients with early T-cell precursor acute lymphoblastic leukemia/lymphoma remained alive in remission. Venetoclax combination therapies are safe, with myelosuppression the main adverse event observed with the addition of venetoclax.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Combination therapies including venetoclax were administered to 13 patients with relapsed/refractory T-ALL at our institution. Marrow responses were achieved in 60% of evaluable patients and 2 patients with early T-cell precursor (ETP) ALL remain alive in remission. Venetoclax combination therapies are safe and myelosuppression was the main adverse event observed with the addition of this drug.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Chemotherapy | Leukemia | Lymphoma | Myeloma | Pediatrics | Science | Toxicology